… Council or Thoracic Society of Australia and New Zealand COPDX guidelines to define a …
bronchodilator reversibility in lung-function laboratories in Australia and New Zealand vary …

… Australian laboratories to agree to a set of standards and apply them universally for spirometry
and reversibility testing. … The COPDX Plan: Australian and New Zealand guidelines for the …

… of baseline FEV 1 ), (iii) the European Thoracic Society (≥10% predicted FEV 1 ), and (iv)
the most commonly used criteria in Australia and New Zealand (≥15% of baseline FEV 1 ). …

… The National Heart Foundation of Australia and the Cardiac Society of Australia and New
Zealand have developed new guidelines to assist Australian clinicians in the care of adult …

… with reversibility such as vitamin K antagonists (warfarin) and dabigatran, which is not
reimbursed by the PBS in Australia, but it is funded by PHARMAC in New Zealand for VTE (…

… of Australia (NHFA) and the Cardiac Society of Australia and New Zealand (CSANZ) to assist
Australian … Treating reversible bleeding risk should be prioritised to minimise the bleeding …

… obstruction across Australian and New Zealand lung function … testing facilities throughout
Australia and New Zealand are … for assessment of reversibility of airflow limitation published …

… Patients presenting to our hospital pulmonary function laboratory, which is accredited by
the Thoracic Society of Australia and New Zealand, were interviewed by a pharmacy intern …

… CBRs were formulated when: (i) the existing intervention evidence base was absent,
ambiguous, or of doubtful clinical impact in the Australian and New Zealand context; and (ii) the …

A transthoracic echocardiogram is recommended in patients with suspected heart failure, to
improve diagnostic accuracy, and in patients with a new diagnosis of heart failure, to assess …